The Role of the Ubiquitination-proteasome Pathway in Breast Cancer: Applying Drugs That Affect the Ubiquitin-proteasome Pathway to the Therapy of Breast Cancer

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2003 Feb 1

PMID 12559038

Citations 58

Authors

Robert Z Orlowski

E Claire Dees

Affiliations

Soon will be listed here.

Abstract

The ubiquitin-proteasome pathway is responsible for most eukaryotic intracellular protein degradation. This pathway has been validated as a target for antineoplastic therapy using both in vitro and preclinical models of human malignancies, and is influenced as part of the mechanism of action of certain chemotherapeutic agents. Drugs whose primary action involves modulation of ubiquitin-proteasome activity, most notably the proteasome inhibitor PS-341, are currently being evaluated in clinical trials, and have already been found to have significant antitumor efficacy. On the basis of the known mechanisms by which these agents work, and the available clinical data, they would seem to be well suited for the treatment of breast neoplasms. Such drugs, alone and especially in combination with current chemotherapeutics, may well represent important advances in the therapy of patients with breast cancer.

Citing Articles

Innovative strategies for minimizing hematoma risk in MRI-guided breast biopsies.

Bronnimann M, McMurray M, Heverhagen J, Christe A, Wyss C, Peters A Radiol Oncol. 2025; 59(1):91-99.

PMID: 39840427 PMC: 11867564. DOI: 10.2478/raon-2025-0004.

Association of Proteasome Activity and Pool Heterogeneity with Markers Determining the Molecular Subtypes of Breast Cancer.

Kondakova I, Sereda E, Sidenko E, Vtorushin S, Vedernikova V, Burov A Cancers (Basel). 2025; 17(1.

PMID: 39796785 PMC: 11720674. DOI: 10.3390/cancers17010159.

Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing.

Murzyn A, Orzel J, Obajtek N, Mroz A, Miodowska D, Bojdo P Cancer Chemother Pharmacol. 2024; 94(2):123-139.

PMID: 38965080 PMC: 11390774. DOI: 10.1007/s00280-024-04693-1.

Chemical Proteomics Reveals that the Anticancer Drug Everolimus Affects the Ubiquitin-Proteasome System.

Lobas A, Saei A, Lyu H, Zubarev R, Gorshkov M ACS Pharmacol Transl Sci. 2024; 7(3):787-796.

PMID: 38481686 PMC: 10928898. DOI: 10.1021/acsptsci.3c00316.

Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment.

Huang M, Shen G, Li N World J Clin Cases. 2022; 10(32):11690-11701.

PMID: 36405275 PMC: 9669866. DOI: 10.12998/wjcc.v10.i32.11690.

References

Teicher B, Ara G, Herbst R, Palombella V, Adams J . The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999; 5(9):2638-45. View

Orlowski R, Baldwin Jr A . NF-kappaB as a therapeutic target in cancer. Trends Mol Med. 2002; 8(8):385-9. DOI: 10.1016/s1471-4914(02)02375-4. View

Jesenberger V, Jentsch S . Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol. 2002; 3(2):112-21. DOI: 10.1038/nrm731. View

Romero A, RABINOVICH M, Vallejo C, Perez J, Rodriguez R, Cuevas M . Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol. 1994; 12(2):336-41. DOI: 10.1200/JCO.1994.12.2.336. View

Figueiredo-Pereira M, Chen W, Li J, Johdo O . The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. J Biol Chem. 1996; 271(28):16455-9. DOI: 10.1074/jbc.271.28.16455. View

Kapahi P, Takahashi T, Natoli G, Adams S, Chen Y, Tsien R . Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem. 2000; 275(46):36062-6. DOI: 10.1074/jbc.M007204200. View

FRANKFURT O, Krishan A . Identification of apoptotic cells by formamide-induced dna denaturation in condensed chromatin. J Histochem Cytochem. 2001; 49(3):369-78. DOI: 10.1177/002215540104900311. View

Wang X, Omura S, Szweda L, Yang Y, Berard J, Seminaro J . Rapamycin inhibits proteasome activator expression and proteasome activity. Eur J Immunol. 1997; 27(11):2781-6. DOI: 10.1002/eji.1830271106. View

Mimnaugh E, Chavany C, Neckers L . Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem. 1996; 271(37):22796-801. DOI: 10.1074/jbc.271.37.22796. View

10.

Orlowski R, Stinchcombe T, Mitchell B, Shea T, Baldwin A, Stahl S . Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002; 20(22):4420-7. DOI: 10.1200/JCO.2002.01.133. View

11.

Glickman M, Ciechanover A . The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002; 82(2):373-428. DOI: 10.1152/physrev.00027.2001. View

12.

Orlowski R, Eswara J, Grever M, Orlowski M, Dang C . Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 1998; 58(19):4342-8. View

13.

Preisler-Mashek M, Solodin N, Stark B, Tyriver M, Alarid E . Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-alpha. Am J Physiol Endocrinol Metab. 2002; 282(4):E891-8. DOI: 10.1152/ajpendo.00353.2001. View

14.

Budd G, Adamson P, Gupta M, Homayoun P, Sandstrom S, Murphy R . Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. Clin Cancer Res. 1998; 4(3):635-42. View

15.

Mao Y, Sun M, Desai S, Liu L . SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage. Proc Natl Acad Sci U S A. 2000; 97(8):4046-51. PMC: 18143. DOI: 10.1073/pnas.080536597. View

16.

Piccinini M, Tazartes O, Mezzatesta C, Ricotti E, Bedino S, Grosso F . Proteasomes are a target of the anti-tumour drug vinblastine. Biochem J. 2001; 356(Pt 3):835-41. PMC: 1221911. DOI: 10.1042/0264-6021:3560835. View

17.

Desterro J, Rodriguez M, Hay R . SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell. 1998; 2(2):233-9. DOI: 10.1016/s1097-2765(00)80133-1. View

18.

Desai S, Liu L, DArpa P . Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem. 1997; 272(39):24159-64. DOI: 10.1074/jbc.272.39.24159. View

19.

Orlowski R, Small G, Shi Y . Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem. 2002; 277(31):27864-71. DOI: 10.1074/jbc.M201519200. View

20.

Perez E, Hillman D, Mailliard J, Ingle J, Ryan J, Fitch T . Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol. 2004; 22(14):2849-55. DOI: 10.1200/JCO.2004.10.047. View